Mobile App for BP Control

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

186 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-01

Study Completion Date

2021-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

SMART-BP is a randomized, controlled study in which hypertensive patients are allocated to self monitoring of blood pressure monitoring (SMBP) only group or SMBP with mobile App based feed-back algorithm (SMBP-App) group. The App based feed-back algorithm will provide the patients with instruction in response to the measured BP value, e.g. remind of taking drug, if high blood pressure is detected.

The primary outcomes are mean systolic BP change and drug compliance at 24-weeks. Secondary endpoints include mean diastolic BP change at 12-week, mean systolic and diastolic BP change at 12 and 24 weeks, and drug compliance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Smartphone App Assisted Home Blood Pressure Monitoring Amongst Hypertensive Patients in Singapore

NCT03209024

Hypertension

UNKNOWN NA

Mobile Phone in Hypertension Management

NCT01510301

Hypertension

COMPLETED NA

Intelligent Hypertension Intervention Study

NCT05526300

To Explore Whether the Application of Intelligent Hypertension Management System Can Effectively Reduce Blood Pressure in Hypertensive Patients

COMPLETED NA

Evaluation of Novel Optical Smartphone Application for Blood Pressure Measurements in Critically Ill Patients

NCT04728477

Hypotension

COMPLETED

Evaluation of a Novel Mobile Phone Application ( OptiBP) for Blood Pressure Monitoring

NCT04121624

Technology

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial is a prospective, randomized, open-label, multicenter trial to evaluate the efficacy of SMBP with mobile health application (SMBP-App) compared with SMBP alone.

Patients with hypertension will be randomly assigned to SMBP-App (intervention) and SMBP along (control) groups. In SMBP group the patients perform home blood pressure measurement and usual care. In SMBP-App group the patients perform home blood pressure and receive extra alarm and instructions from the mobile application in response to the obtained blood pressure value.

The aim of this study is to evaluate whether SMBP-App is superior to SMBP alone in terms of blood pressure reduction and improved drug compliance in patients with hypertension.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SMBP_only

Standard treatment with SMBP

Group Type ACTIVE_COMPARATOR

Standard SMBP

Intervention Type OTHER

Standard treatment (SMBP-alone)

SMBP_mobile_app

SMBP with mobile App based feed-back algorithm

Group Type EXPERIMENTAL

Mobile Application

Intervention Type OTHER

SMBP with mobile App based feed-back algorithm. The App based feed-back algorithm will remind the patients of taking drug to improve BP control and drug compliance.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mobile Application

SMBP with mobile App based feed-back algorithm. The App based feed-back algorithm will remind the patients of taking drug to improve BP control and drug compliance.

Intervention Type OTHER

Standard SMBP

Standard treatment (SMBP-alone)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female patients with essential hypertension aged 19 years and above.
2. Patients with essential hypertension who are taking one or more antihypertensive drugs.
3. Patients whose average systolic and diastolic BP measured 3 times on the reference arm in the sitting position during Visit 1 is greater than 140 mmHg and 90 mmHg, respectively.
4. Patients voluntarily consent to participate in this clinical trial
5. Patients who can use a smartphone

Exclusion Criteria

1. Patients with a history of secondary hypertension or suspected secondary hypertension, including coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma, and polycystic kidney disease.
2. Patients with a mean systolic BP ≥ 200 mmHg or diastolic BP ≥ 110 mmHg at the screening visit.
3. Patients with ≥ 20 mmHg difference between the highest and the lowest sitting systolic BP or ≥ 10 mmHg difference between highest and lowest diastolic BP, which is confirmed by triplicate measurements from the reference arm at screening.
4. Patients with uncontrolled diabetes (HbA1c ≥ 9.0%).
5. Patients who have been continuously taking other medications such as systemic steroids, thyroid hormones, oral contraceptives (except for menopausal hormone replacement therapy), psychiatric drugs, non-steroidal anti-inflammatory drugs, sympathetic drugs, and immune suppressants, which have the potential to affect BP.
6. Patients with symptomatic orthostatic hypotension.
7. Patients with a history of malignant tumors, including leukemia and lymphoma, within the past 5 years.
8. Patients with a history of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus.
9. Patients with clinically significant kidney and liver diseases, such as those on dialysis, liver cirrhosis, biliary obstruction, and hepatic failure, or those who show the following findings during the screening visit:

* Alanine transaminase or aspartate transaminase level is at least 3 times higher than the normal upper limit;
* Total bilirubin level is more than twice the normal upper limit;
* Blood urea nitrogen level is more than twice the normal upper limit;
* Alkaline phosphatase level is more than twice the normal upper limit;
* Creatinine clearance level is less than 10 mL/min.
10. Patients with a history of the following diseases in the past 6 months, which are determined to be clinically significant by the investigator:

* Heart failure (NYHA class III and IV), ischemic heart diseases (coronary artery diseases, such as angina pectoris and myocardial infarction), peripheral vascular diseases, hemodynamically significant valve stenosis, and arrhythmia.
* Severe cerebrovascular events, including stroke, cerebral infarction, and cerebral hemorrhage.
11. Patients with shock.
12. Patients with a history of alcohol or drug abuse.
13. Patients with potential pregnancy or breastfeeding.
14. Patients who will be judged as both legally and psychologically inadequate to participate in the clinical study by the investigator.
15. Patients who have participated in clinical studies with other investigational drug products within 4 weeks prior to screening.

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No